Latest:
Dr. Greene on the Future of Personalized Therapy in Prostate Cancer
Kirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Matthew J. Wieduwilt, MD, PhD
Latest:
Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL
Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.
Ahmad Abdelfattah Al-Hader, MD
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for Fellows
Investigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, is a nurse practitioner in the Multiple Myeloma Program at Cleveland Clinic in Ohio.
Latest:
Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.
Praveen Vikas, MBBS
Latest:
MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast Cancer
Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Estelamari Rodriguez, MD, MPH
Estelamari Rodriguez, MD, MPH, is associate director of Community Outreach – Thoracic Oncology at Sylvester Comprehensive Cancer Center.
Latest:
Navigating Novel IO Regimens and ADCs in Lung Cancer With Drs Rodriguez, Olazagasti, and Roy
Estelamari Rodriguez, MD, MPH, Coral Olazagasti, MD, and Tina Roy, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Rona Yaeger, MD
Rona Yaeger, MD, is an associate attending physician, gastrointestinal medical oncologist, and early drug development specialist at the Memorial Sloan Kettering Cancer Center in New York.
Latest:
Dr Yaeger on the Efficacy of Adagrasib/Cetuximab in KRAS G12C+ mCRC
Rona Yaeger, MD, details the efficacy of adagrasib/cetuximab in heavily pretreated patients with KRAS G12C–mutant mCRC.
Rabi Upadhyay, MD
Rabi Upadhyay, MD, an instructor in the Department of Medicine at NYU Langone Health's Perlmutter Cancer Center
Latest:
Fellows on Film: What Makes a Good Mentor for an Oncology Fellow?
Michael L. Grossbard, MD, and Rabi Upadhyay, MD, Instructor, Department of Medicine at NYU Grossman School of Medicine, discuss the qualities that make someone a great mentor for an oncology fellow.
Yair Lotan, MD
Yair Lotan, MD, is a professor of urology, chief of Urologic Oncology, and holder of the Jane and John Juston Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, MD, the University of Texas (UT) Southwestern Harold C. Simmons Comprehensive Cancer Center; as well as the medical director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System
Latest:
Dr Lotan on Guideline-Supported Treatment Decision-Making for NMIBC
Yair Lotan, MD, discusses guideline-supported treatment avenues for patients with BCG-unresponsive NMIBC.